Cargando…
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the che...
Autores principales: | Mosna, Federico, Capelli, Debora, Gottardi, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483867/ https://www.ncbi.nlm.nih.gov/pubmed/28587190 http://dx.doi.org/10.3390/jcm6060057 |
Ejemplares similares
-
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia
por: Mosna, Federico, et al.
Publicado: (2016) -
Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020) -
Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021) -
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
por: Gottardi, Michele, et al.
Publicado: (2017) -
Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)